InvestWiser

Medivir AB

MVIRNasdaq StockholmHealthcareMarket value 680 m SEK
1.09SEK −2.7%
last day · Price as of 18 November 2026

The answer first

Does Medivir beat the market?

Yes, Medivir has beaten the market over the last year.

Medivir+150.3%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 25% of Nordic stocks

    • Quality76
    • Value8
    • Trend34

    No. 117 of 195 in healthcare

Max for seven days

Follow Medivir with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Medivir

From today, at a price of 1.09 SEK. Write why you follow Medivir, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Medivir

Your first answer is free, no account needed.

Do you own Medivir, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Medivir and a few more. Free, no card.

Past year against the exchange and Super Stock
Medivir+168.1%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Medivir has risen 150.3% over the past year, including dividends.
  • Overall, Medivir ranks better than 25% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 95.7%. The price is 99.3% below its peak now.

What do analysts think of Medivir?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

25

Quality, value and trend together. Better than 25% of Nordic stocks.

No. 117 of 195 in healthcare

Quality76
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 68 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.03
  • Asset turnoverSales divided by everything the company owns0.03
  • Return on equityProfit divided by equity−30.6%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value8
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 147 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity2.3
  • P/SPrice divided by sales79.8
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend34
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 99 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−42.6%
  • 6 months−45.6%
  • 9 months−19.3%
  • 12 months+150.3%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−27.8%
3 years, per year
−31.2%
5 years, per year
−33.9%
10 years, per year
−31.8%
Largest fall, 3 years
−95.7%
From a peak to the bottom
From the peak now
−99.3%
How far the price is from the peak
Volatility, 1 year
141.3%
How much the price swings over a year
Beta, 1 year
1.39
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Medivir

6 funds we follow own Medivir. The share is how much of the fund the stock makes up.

  • Sweden6

From the funds' latest known holdings.

About Medivir

Medivir AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C.

See the full analysis of Medivir.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market